Immunomodulatory Effect of Ulinastatin in Patients with Acute Lung Injury
- VernacularTitle:乌司他丁对急性肺损伤患者的免疫调节作用
- Author:
Hongzhi LI
1
;
Jie SHEN
;
Zhiyue ZHONG
;
Siqing MIN
Author Information
1. 复旦大学附属金山医院重症监护室
- Keywords:
Acute lung injury;
Ulinastatin;
Immunomodulation
- From:
Chinese Journal of Clinical Medicine
2015;(3):343-345,348
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate immunomodulatory effect of ulinastatin in patients with acute lung injury (ALI) .Methods:Thirty patients ,who accorded with diagnostic criteria of ALI ,were randomly assigned to the control group (14 cases) or the treatment group (16 cases) .The patients in the control group were treated with regular therapy ,while those in the treatment group received 7 days’ treatment with ulinastatin in addition .The acute physiology and chronic health evaluation(APACHE)Ⅱscore was evaluated for the patients in two groups before and after the treatment ,while the oxygenation index was calculated . The concentrations of tumor necrosis factor alpha (TNF‐α) and interleukin‐6 ,8 ,10 (IL‐6 ,8 ,10) were determined by enzyme‐linked immunosorbent assay and the percentages of peripheral blood T lymphocyte subsets (CD3+ 、CD4+ 、CD8+ ) was detected by flow cytometry .The immune globulin (IgA ,IgG ,IgE ,IgM )was detected .The length of ICU stay and mortality were coun‐ted .Results:After the treatment ,the APACHEⅡ score and Oxygenation index in the treatment group were much lower than those in the control group .The expression of peripheral blood T lymphocyte subsets(CD3+ 、CD4+ 、CD8+ ) in the treatment af‐ter the treatment was much higher than that before the treatment .The levels of TNF‐αand IL‐6 ,8 ,10 in the treatment group were significantly lower than those in the control group .The length of ICU stay decreased and the difference was statistically significant(P<0 .05) .However ,no significant difference was found in the immune globulin IgA ,IgG ,IgE ,IgM and the mor‐tality (P>0 .05) .Conclusions:Ulinastatin ,in a certain extent ,improves the immune function of patients with ALI ,especially for cellular immune enhancement .
